nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—ABCB1—melanoma	0.187	1	CbGaD
Citalopram—CYP2E1—Dacarbazine—melanoma	0.0818	0.172	CbGbCtD
Citalopram—CYP1A2—Carmustine—melanoma	0.078	0.164	CbGbCtD
Citalopram—CYP1A2—Vemurafenib—melanoma	0.0617	0.129	CbGbCtD
Citalopram—CYP3A4—Temozolomide—melanoma	0.059	0.124	CbGbCtD
Citalopram—CYP2D6—Vemurafenib—melanoma	0.0508	0.107	CbGbCtD
Citalopram—CYP1A2—Dacarbazine—melanoma	0.0473	0.0993	CbGbCtD
Citalopram—ABCB1—Dactinomycin—melanoma	0.0358	0.0753	CbGbCtD
Citalopram—CYP3A4—Vemurafenib—melanoma	0.0323	0.0678	CbGbCtD
Citalopram—ABCB1—Docetaxel—melanoma	0.0185	0.0389	CbGbCtD
Citalopram—CYP3A4—Docetaxel—melanoma	0.0111	0.0233	CbGbCtD
Citalopram—Orthostatic hypotension—Docetaxel—melanoma	0.000211	0.000877	CcSEcCtD
Citalopram—Rash—Vemurafenib—melanoma	0.000211	0.000876	CcSEcCtD
Citalopram—Mental disorder—Temozolomide—melanoma	0.000211	0.000875	CcSEcCtD
Citalopram—Dermatitis—Vemurafenib—melanoma	0.000211	0.000875	CcSEcCtD
Citalopram—Back pain—Carmustine—melanoma	0.00021	0.000871	CcSEcCtD
Citalopram—Headache—Vemurafenib—melanoma	0.00021	0.00087	CcSEcCtD
Citalopram—Malnutrition—Temozolomide—melanoma	0.00021	0.00087	CcSEcCtD
Citalopram—Erythema—Temozolomide—melanoma	0.00021	0.00087	CcSEcCtD
Citalopram—Breast disorder—Docetaxel—melanoma	0.000209	0.000868	CcSEcCtD
Citalopram—Discomfort—Bleomycin—melanoma	0.000209	0.000867	CcSEcCtD
Citalopram—Malaise—Dactinomycin—melanoma	0.000209	0.000867	CcSEcCtD
Citalopram—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000209	0.000865	CcSEcCtD
Citalopram—Cramp muscle—Docetaxel—melanoma	0.000209	0.000865	CcSEcCtD
Citalopram—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000209	0.000865	CcSEcCtD
Citalopram—Leukopenia—Dactinomycin—melanoma	0.000208	0.000861	CcSEcCtD
Citalopram—Nasopharyngitis—Docetaxel—melanoma	0.000207	0.000859	CcSEcCtD
Citalopram—Dysgeusia—Temozolomide—melanoma	0.000205	0.000852	CcSEcCtD
Citalopram—Confusional state—Bleomycin—melanoma	0.000205	0.000849	CcSEcCtD
Citalopram—Vision blurred—Carmustine—melanoma	0.000205	0.000848	CcSEcCtD
Citalopram—Alanine aminotransferase increased—Docetaxel—melanoma	0.000204	0.000847	CcSEcCtD
Citalopram—Tremor—Carmustine—melanoma	0.000203	0.000843	CcSEcCtD
Citalopram—Anaphylactic shock—Bleomycin—melanoma	0.000203	0.000842	CcSEcCtD
Citalopram—Oedema—Bleomycin—melanoma	0.000203	0.000842	CcSEcCtD
Citalopram—Back pain—Temozolomide—melanoma	0.000203	0.000841	CcSEcCtD
Citalopram—Infection—Bleomycin—melanoma	0.000202	0.000836	CcSEcCtD
Citalopram—Anaemia—Carmustine—melanoma	0.000201	0.000832	CcSEcCtD
Citalopram—Dysphagia—Docetaxel—melanoma	0.0002	0.00083	CcSEcCtD
Citalopram—Agitation—Carmustine—melanoma	0.000199	0.000827	CcSEcCtD
Citalopram—Nausea—Vemurafenib—melanoma	0.000199	0.000825	CcSEcCtD
Citalopram—Thrombocytopenia—Bleomycin—melanoma	0.000199	0.000824	CcSEcCtD
Citalopram—Vision blurred—Temozolomide—melanoma	0.000198	0.00082	CcSEcCtD
Citalopram—Myalgia—Dactinomycin—melanoma	0.000197	0.000819	CcSEcCtD
Citalopram—Bronchospasm—Docetaxel—melanoma	0.000197	0.000817	CcSEcCtD
Citalopram—Tremor—Temozolomide—melanoma	0.000196	0.000815	CcSEcCtD
Citalopram—Discomfort—Dactinomycin—melanoma	0.000195	0.000809	CcSEcCtD
Citalopram—Angina pectoris—Docetaxel—melanoma	0.000195	0.000809	CcSEcCtD
Citalopram—Ill-defined disorder—Temozolomide—melanoma	0.000195	0.000807	CcSEcCtD
Citalopram—Leukopenia—Carmustine—melanoma	0.000194	0.000806	CcSEcCtD
Citalopram—Anaemia—Temozolomide—melanoma	0.000194	0.000804	CcSEcCtD
Citalopram—Anorexia—Bleomycin—melanoma	0.000193	0.000802	CcSEcCtD
Citalopram—Agitation—Temozolomide—melanoma	0.000193	0.000799	CcSEcCtD
Citalopram—Angioedema—Temozolomide—melanoma	0.000192	0.000795	CcSEcCtD
Citalopram—Pancytopenia—Docetaxel—melanoma	0.00019	0.000788	CcSEcCtD
Citalopram—Hypotension—Bleomycin—melanoma	0.00019	0.000786	CcSEcCtD
Citalopram—Oedema—Dactinomycin—melanoma	0.000189	0.000785	CcSEcCtD
Citalopram—Malaise—Temozolomide—melanoma	0.000189	0.000784	CcSEcCtD
Citalopram—Vertigo—Temozolomide—melanoma	0.000188	0.000781	CcSEcCtD
Citalopram—Convulsion—Carmustine—melanoma	0.000188	0.00078	CcSEcCtD
Citalopram—Infection—Dactinomycin—melanoma	0.000188	0.00078	CcSEcCtD
Citalopram—Leukopenia—Temozolomide—melanoma	0.000188	0.000779	CcSEcCtD
Citalopram—Hypertension—Carmustine—melanoma	0.000187	0.000777	CcSEcCtD
Citalopram—Palpitations—Temozolomide—melanoma	0.000185	0.000769	CcSEcCtD
Citalopram—Thrombocytopenia—Dactinomycin—melanoma	0.000185	0.000768	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Bleomycin—melanoma	0.000185	0.000767	CcSEcCtD
Citalopram—Myalgia—Carmustine—melanoma	0.000185	0.000766	CcSEcCtD
Citalopram—Chest pain—Carmustine—melanoma	0.000185	0.000766	CcSEcCtD
Citalopram—Anxiety—Carmustine—melanoma	0.000184	0.000764	CcSEcCtD
Citalopram—Cough—Temozolomide—melanoma	0.000183	0.000759	CcSEcCtD
Citalopram—Paraesthesia—Bleomycin—melanoma	0.000182	0.000756	CcSEcCtD
Citalopram—Weight increased—Docetaxel—melanoma	0.000182	0.000755	CcSEcCtD
Citalopram—Convulsion—Temozolomide—melanoma	0.000182	0.000754	CcSEcCtD
Citalopram—Weight decreased—Docetaxel—melanoma	0.000181	0.000751	CcSEcCtD
Citalopram—Hypertension—Temozolomide—melanoma	0.000181	0.000751	CcSEcCtD
Citalopram—Dyspnoea—Bleomycin—melanoma	0.000181	0.00075	CcSEcCtD
Citalopram—Anorexia—Dactinomycin—melanoma	0.00018	0.000748	CcSEcCtD
Citalopram—Pneumonia—Docetaxel—melanoma	0.000179	0.000744	CcSEcCtD
Citalopram—Confusional state—Carmustine—melanoma	0.000179	0.000741	CcSEcCtD
Citalopram—Arthralgia—Temozolomide—melanoma	0.000179	0.000741	CcSEcCtD
Citalopram—Myalgia—Temozolomide—melanoma	0.000179	0.000741	CcSEcCtD
Citalopram—Infestation NOS—Docetaxel—melanoma	0.000178	0.00074	CcSEcCtD
Citalopram—Infestation—Docetaxel—melanoma	0.000178	0.00074	CcSEcCtD
Citalopram—Anxiety—Temozolomide—melanoma	0.000178	0.000738	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000177	0.000735	CcSEcCtD
Citalopram—Oedema—Carmustine—melanoma	0.000177	0.000735	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000177	0.000734	CcSEcCtD
Citalopram—Discomfort—Temozolomide—melanoma	0.000176	0.000732	CcSEcCtD
Citalopram—Decreased appetite—Bleomycin—melanoma	0.000176	0.000732	CcSEcCtD
Citalopram—Infection—Carmustine—melanoma	0.000176	0.00073	CcSEcCtD
Citalopram—Acute coronary syndrome—Docetaxel—melanoma	0.000176	0.00073	CcSEcCtD
Citalopram—Neuropathy peripheral—Docetaxel—melanoma	0.000175	0.000726	CcSEcCtD
Citalopram—Myocardial infarction—Docetaxel—melanoma	0.000175	0.000726	CcSEcCtD
Citalopram—Dry mouth—Temozolomide—melanoma	0.000175	0.000724	CcSEcCtD
Citalopram—Jaundice—Docetaxel—melanoma	0.000174	0.000721	CcSEcCtD
Citalopram—Stomatitis—Docetaxel—melanoma	0.000174	0.000721	CcSEcCtD
Citalopram—Pain—Bleomycin—melanoma	0.000173	0.00072	CcSEcCtD
Citalopram—Conjunctivitis—Docetaxel—melanoma	0.000173	0.000719	CcSEcCtD
Citalopram—Thrombocytopenia—Carmustine—melanoma	0.000173	0.000719	CcSEcCtD
Citalopram—Tachycardia—Carmustine—melanoma	0.000173	0.000717	CcSEcCtD
Citalopram—Confusional state—Temozolomide—melanoma	0.000173	0.000716	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000172	0.000715	CcSEcCtD
Citalopram—Anaphylactic shock—Temozolomide—melanoma	0.000171	0.00071	CcSEcCtD
Citalopram—Oedema—Temozolomide—melanoma	0.000171	0.00071	CcSEcCtD
Citalopram—Infection—Temozolomide—melanoma	0.00017	0.000705	CcSEcCtD
Citalopram—Anorexia—Carmustine—melanoma	0.000169	0.0007	CcSEcCtD
Citalopram—Hepatobiliary disease—Docetaxel—melanoma	0.000169	0.0007	CcSEcCtD
Citalopram—Epistaxis—Docetaxel—melanoma	0.000168	0.000698	CcSEcCtD
Citalopram—Nervous system disorder—Temozolomide—melanoma	0.000168	0.000696	CcSEcCtD
Citalopram—Thrombocytopenia—Temozolomide—melanoma	0.000168	0.000695	CcSEcCtD
Citalopram—Feeling abnormal—Bleomycin—melanoma	0.000167	0.000693	CcSEcCtD
Citalopram—Agranulocytosis—Docetaxel—melanoma	0.000167	0.000691	CcSEcCtD
Citalopram—Skin disorder—Temozolomide—melanoma	0.000166	0.00069	CcSEcCtD
Citalopram—Hypotension—Carmustine—melanoma	0.000165	0.000686	CcSEcCtD
Citalopram—Hyperhidrosis—Temozolomide—melanoma	0.000165	0.000686	CcSEcCtD
Citalopram—Decreased appetite—Dactinomycin—melanoma	0.000164	0.000682	CcSEcCtD
Citalopram—Fatigue—Dactinomycin—melanoma	0.000163	0.000677	CcSEcCtD
Citalopram—Anorexia—Temozolomide—melanoma	0.000163	0.000677	CcSEcCtD
Citalopram—Pain—Dactinomycin—melanoma	0.000162	0.000671	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Carmustine—melanoma	0.000161	0.000669	CcSEcCtD
Citalopram—Urticaria—Bleomycin—melanoma	0.000161	0.000669	CcSEcCtD
Citalopram—Haemoglobin—Docetaxel—melanoma	0.000161	0.000668	CcSEcCtD
Citalopram—Rhinitis—Docetaxel—melanoma	0.000161	0.000666	CcSEcCtD
Citalopram—Body temperature increased—Bleomycin—melanoma	0.00016	0.000665	CcSEcCtD
Citalopram—Haemorrhage—Docetaxel—melanoma	0.00016	0.000664	CcSEcCtD
Citalopram—Hepatitis—Docetaxel—melanoma	0.00016	0.000664	CcSEcCtD
Citalopram—Insomnia—Carmustine—melanoma	0.00016	0.000664	CcSEcCtD
Citalopram—Hypoaesthesia—Docetaxel—melanoma	0.000159	0.000661	CcSEcCtD
Citalopram—Paraesthesia—Carmustine—melanoma	0.000159	0.00066	CcSEcCtD
Citalopram—Pharyngitis—Docetaxel—melanoma	0.000159	0.000659	CcSEcCtD
Citalopram—Urinary tract disorder—Docetaxel—melanoma	0.000158	0.000656	CcSEcCtD
Citalopram—Dyspnoea—Carmustine—melanoma	0.000158	0.000655	CcSEcCtD
Citalopram—Oedema peripheral—Docetaxel—melanoma	0.000158	0.000655	CcSEcCtD
Citalopram—Somnolence—Carmustine—melanoma	0.000157	0.000653	CcSEcCtD
Citalopram—Connective tissue disorder—Docetaxel—melanoma	0.000157	0.000653	CcSEcCtD
Citalopram—Urethral disorder—Docetaxel—melanoma	0.000157	0.000651	CcSEcCtD
Citalopram—Feeling abnormal—Dactinomycin—melanoma	0.000156	0.000647	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Temozolomide—melanoma	0.000156	0.000647	CcSEcCtD
Citalopram—Insomnia—Temozolomide—melanoma	0.000155	0.000642	CcSEcCtD
Citalopram—Gastrointestinal pain—Dactinomycin—melanoma	0.000155	0.000642	CcSEcCtD
Citalopram—Visual impairment—Docetaxel—melanoma	0.000154	0.00064	CcSEcCtD
Citalopram—Decreased appetite—Carmustine—melanoma	0.000154	0.000639	CcSEcCtD
Citalopram—Paraesthesia—Temozolomide—melanoma	0.000154	0.000637	CcSEcCtD
Citalopram—Gastrointestinal disorder—Carmustine—melanoma	0.000153	0.000634	CcSEcCtD
Citalopram—Dyspnoea—Temozolomide—melanoma	0.000153	0.000633	CcSEcCtD
Citalopram—Somnolence—Temozolomide—melanoma	0.000152	0.000631	CcSEcCtD
Citalopram—Erythema multiforme—Docetaxel—melanoma	0.000151	0.000628	CcSEcCtD
Citalopram—Pain—Carmustine—melanoma	0.000151	0.000628	CcSEcCtD
Citalopram—Constipation—Carmustine—melanoma	0.000151	0.000628	CcSEcCtD
Citalopram—Dyspepsia—Temozolomide—melanoma	0.000151	0.000625	CcSEcCtD
Citalopram—Eye disorder—Docetaxel—melanoma	0.00015	0.000621	CcSEcCtD
Citalopram—Abdominal pain—Dactinomycin—melanoma	0.00015	0.00062	CcSEcCtD
Citalopram—Body temperature increased—Dactinomycin—melanoma	0.00015	0.00062	CcSEcCtD
Citalopram—Hypersensitivity—Bleomycin—melanoma	0.000149	0.00062	CcSEcCtD
Citalopram—Decreased appetite—Temozolomide—melanoma	0.000149	0.000617	CcSEcCtD
Citalopram—Cardiac disorder—Docetaxel—melanoma	0.000149	0.000617	CcSEcCtD
Citalopram—Flushing—Docetaxel—melanoma	0.000149	0.000617	CcSEcCtD
Citalopram—Gastrointestinal disorder—Temozolomide—melanoma	0.000148	0.000613	CcSEcCtD
Citalopram—Fatigue—Temozolomide—melanoma	0.000148	0.000612	CcSEcCtD
Citalopram—Pain—Temozolomide—melanoma	0.000146	0.000607	CcSEcCtD
Citalopram—Constipation—Temozolomide—melanoma	0.000146	0.000607	CcSEcCtD
Citalopram—Feeling abnormal—Carmustine—melanoma	0.000146	0.000605	CcSEcCtD
Citalopram—Asthenia—Bleomycin—melanoma	0.000146	0.000604	CcSEcCtD
Citalopram—Angiopathy—Docetaxel—melanoma	0.000145	0.000603	CcSEcCtD
Citalopram—Gastrointestinal pain—Carmustine—melanoma	0.000145	0.000601	CcSEcCtD
Citalopram—Immune system disorder—Docetaxel—melanoma	0.000145	0.0006	CcSEcCtD
Citalopram—Mediastinal disorder—Docetaxel—melanoma	0.000144	0.000599	CcSEcCtD
Citalopram—Chills—Docetaxel—melanoma	0.000144	0.000596	CcSEcCtD
Citalopram—Pruritus—Bleomycin—melanoma	0.000144	0.000595	CcSEcCtD
Citalopram—Arrhythmia—Docetaxel—melanoma	0.000143	0.000594	CcSEcCtD
Citalopram—Alopecia—Docetaxel—melanoma	0.000142	0.000587	CcSEcCtD
Citalopram—Feeling abnormal—Temozolomide—melanoma	0.000141	0.000585	CcSEcCtD
Citalopram—Mental disorder—Docetaxel—melanoma	0.00014	0.000582	CcSEcCtD
Citalopram—Body temperature increased—Carmustine—melanoma	0.00014	0.000581	CcSEcCtD
Citalopram—Abdominal pain—Carmustine—melanoma	0.00014	0.000581	CcSEcCtD
Citalopram—Gastrointestinal pain—Temozolomide—melanoma	0.00014	0.00058	CcSEcCtD
Citalopram—Erythema—Docetaxel—melanoma	0.000139	0.000578	CcSEcCtD
Citalopram—Malnutrition—Docetaxel—melanoma	0.000139	0.000578	CcSEcCtD
Citalopram—Hypersensitivity—Dactinomycin—melanoma	0.000139	0.000578	CcSEcCtD
Citalopram—Dysgeusia—Docetaxel—melanoma	0.000137	0.000566	CcSEcCtD
Citalopram—Urticaria—Temozolomide—melanoma	0.000136	0.000564	CcSEcCtD
Citalopram—Asthenia—Dactinomycin—melanoma	0.000136	0.000563	CcSEcCtD
Citalopram—Body temperature increased—Temozolomide—melanoma	0.000135	0.000561	CcSEcCtD
Citalopram—Abdominal pain—Temozolomide—melanoma	0.000135	0.000561	CcSEcCtD
Citalopram—Back pain—Docetaxel—melanoma	0.000135	0.00056	CcSEcCtD
Citalopram—Muscle spasms—Docetaxel—melanoma	0.000134	0.000556	CcSEcCtD
Citalopram—Hypersensitivity—Carmustine—melanoma	0.00013	0.000541	CcSEcCtD
Citalopram—Diarrhoea—Dactinomycin—melanoma	0.000129	0.000537	CcSEcCtD
Citalopram—Vomiting—Bleomycin—melanoma	0.000129	0.000535	CcSEcCtD
Citalopram—Anaemia—Docetaxel—melanoma	0.000129	0.000535	CcSEcCtD
Citalopram—Rash—Bleomycin—melanoma	0.000128	0.000531	CcSEcCtD
Citalopram—Dermatitis—Bleomycin—melanoma	0.000128	0.00053	CcSEcCtD
Citalopram—Asthenia—Carmustine—melanoma	0.000127	0.000527	CcSEcCtD
Citalopram—Hypersensitivity—Temozolomide—melanoma	0.000126	0.000523	CcSEcCtD
Citalopram—Syncope—Docetaxel—melanoma	0.000125	0.000519	CcSEcCtD
Citalopram—Leukopenia—Docetaxel—melanoma	0.000125	0.000518	CcSEcCtD
Citalopram—Palpitations—Docetaxel—melanoma	0.000123	0.000511	CcSEcCtD
Citalopram—Asthenia—Temozolomide—melanoma	0.000123	0.000509	CcSEcCtD
Citalopram—Loss of consciousness—Docetaxel—melanoma	0.000123	0.000508	CcSEcCtD
Citalopram—Cough—Docetaxel—melanoma	0.000122	0.000505	CcSEcCtD
Citalopram—Diarrhoea—Carmustine—melanoma	0.000121	0.000503	CcSEcCtD
Citalopram—Pruritus—Temozolomide—melanoma	0.000121	0.000502	CcSEcCtD
Citalopram—Convulsion—Docetaxel—melanoma	0.000121	0.000501	CcSEcCtD
Citalopram—Nausea—Bleomycin—melanoma	0.000121	0.0005	CcSEcCtD
Citalopram—Hypertension—Docetaxel—melanoma	0.00012	0.000499	CcSEcCtD
Citalopram—Vomiting—Dactinomycin—melanoma	0.00012	0.000499	CcSEcCtD
Citalopram—Rash—Dactinomycin—melanoma	0.000119	0.000495	CcSEcCtD
Citalopram—Arthralgia—Docetaxel—melanoma	0.000119	0.000492	CcSEcCtD
Citalopram—Chest pain—Docetaxel—melanoma	0.000119	0.000492	CcSEcCtD
Citalopram—Myalgia—Docetaxel—melanoma	0.000119	0.000492	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000118	0.000489	CcSEcCtD
Citalopram—Dizziness—Carmustine—melanoma	0.000117	0.000486	CcSEcCtD
Citalopram—Diarrhoea—Temozolomide—melanoma	0.000117	0.000486	CcSEcCtD
Citalopram—Dry mouth—Docetaxel—melanoma	0.000116	0.000482	CcSEcCtD
Citalopram—Confusional state—Docetaxel—melanoma	0.000115	0.000476	CcSEcCtD
Citalopram—Anaphylactic shock—Docetaxel—melanoma	0.000114	0.000472	CcSEcCtD
Citalopram—Oedema—Docetaxel—melanoma	0.000114	0.000472	CcSEcCtD
Citalopram—Dizziness—Temozolomide—melanoma	0.000113	0.000469	CcSEcCtD
Citalopram—Infection—Docetaxel—melanoma	0.000113	0.000469	CcSEcCtD
Citalopram—Vomiting—Carmustine—melanoma	0.000113	0.000467	CcSEcCtD
Citalopram—Nausea—Dactinomycin—melanoma	0.000112	0.000466	CcSEcCtD
Citalopram—Shock—Docetaxel—melanoma	0.000112	0.000464	CcSEcCtD
Citalopram—Rash—Carmustine—melanoma	0.000112	0.000463	CcSEcCtD
Citalopram—Nervous system disorder—Docetaxel—melanoma	0.000112	0.000463	CcSEcCtD
Citalopram—Dermatitis—Carmustine—melanoma	0.000112	0.000463	CcSEcCtD
Citalopram—Thrombocytopenia—Docetaxel—melanoma	0.000111	0.000462	CcSEcCtD
Citalopram—Tachycardia—Docetaxel—melanoma	0.000111	0.000461	CcSEcCtD
Citalopram—Headache—Carmustine—melanoma	0.000111	0.00046	CcSEcCtD
Citalopram—Skin disorder—Docetaxel—melanoma	0.000111	0.000459	CcSEcCtD
Citalopram—Vomiting—Temozolomide—melanoma	0.000109	0.000451	CcSEcCtD
Citalopram—Anorexia—Docetaxel—melanoma	0.000108	0.00045	CcSEcCtD
Citalopram—Rash—Temozolomide—melanoma	0.000108	0.000448	CcSEcCtD
Citalopram—Dermatitis—Temozolomide—melanoma	0.000108	0.000447	CcSEcCtD
Citalopram—Headache—Temozolomide—melanoma	0.000107	0.000445	CcSEcCtD
Citalopram—Hypotension—Docetaxel—melanoma	0.000106	0.000441	CcSEcCtD
Citalopram—Nausea—Carmustine—melanoma	0.000105	0.000436	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Docetaxel—melanoma	0.000104	0.00043	CcSEcCtD
Citalopram—Insomnia—Docetaxel—melanoma	0.000103	0.000427	CcSEcCtD
Citalopram—Paraesthesia—Docetaxel—melanoma	0.000102	0.000424	CcSEcCtD
Citalopram—Nausea—Temozolomide—melanoma	0.000102	0.000422	CcSEcCtD
Citalopram—Dyspnoea—Docetaxel—melanoma	0.000101	0.000421	CcSEcCtD
Citalopram—Somnolence—Docetaxel—melanoma	0.000101	0.00042	CcSEcCtD
Citalopram—Dyspepsia—Docetaxel—melanoma	0.0001	0.000416	CcSEcCtD
Citalopram—Decreased appetite—Docetaxel—melanoma	9.89e-05	0.00041	CcSEcCtD
Citalopram—Gastrointestinal disorder—Docetaxel—melanoma	9.83e-05	0.000408	CcSEcCtD
Citalopram—Fatigue—Docetaxel—melanoma	9.81e-05	0.000407	CcSEcCtD
Citalopram—Pain—Docetaxel—melanoma	9.73e-05	0.000404	CcSEcCtD
Citalopram—Constipation—Docetaxel—melanoma	9.73e-05	0.000404	CcSEcCtD
Citalopram—Feeling abnormal—Docetaxel—melanoma	9.38e-05	0.000389	CcSEcCtD
Citalopram—Gastrointestinal pain—Docetaxel—melanoma	9.31e-05	0.000386	CcSEcCtD
Citalopram—Body temperature increased—Docetaxel—melanoma	9e-05	0.000373	CcSEcCtD
Citalopram—Abdominal pain—Docetaxel—melanoma	9e-05	0.000373	CcSEcCtD
Citalopram—Hypersensitivity—Docetaxel—melanoma	8.39e-05	0.000348	CcSEcCtD
Citalopram—Asthenia—Docetaxel—melanoma	8.17e-05	0.000339	CcSEcCtD
Citalopram—Pruritus—Docetaxel—melanoma	8.05e-05	0.000334	CcSEcCtD
Citalopram—Diarrhoea—Docetaxel—melanoma	7.79e-05	0.000323	CcSEcCtD
Citalopram—Dizziness—Docetaxel—melanoma	7.53e-05	0.000312	CcSEcCtD
Citalopram—Vomiting—Docetaxel—melanoma	7.24e-05	0.0003	CcSEcCtD
Citalopram—Rash—Docetaxel—melanoma	7.18e-05	0.000298	CcSEcCtD
Citalopram—Dermatitis—Docetaxel—melanoma	7.17e-05	0.000297	CcSEcCtD
Citalopram—Headache—Docetaxel—melanoma	7.13e-05	0.000296	CcSEcCtD
Citalopram—Nausea—Docetaxel—melanoma	6.76e-05	0.00028	CcSEcCtD
Citalopram—CHRM1—Signaling Pathways—PIK3CG—melanoma	6.54e-06	6.82e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—NRAS—melanoma	6.54e-06	6.82e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—KRAS—melanoma	6.51e-06	6.8e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGF—melanoma	6.48e-06	6.77e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PPARG—melanoma	6.47e-06	6.75e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PRKCA—melanoma	6.47e-06	6.75e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ABCB1—melanoma	6.47e-06	6.75e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGF—melanoma	6.46e-06	6.75e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CD80—melanoma	6.45e-06	6.73e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KIT—melanoma	6.44e-06	6.72e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—APC—melanoma	6.44e-06	6.72e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CG—melanoma	6.44e-06	6.72e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—NRAS—melanoma	6.44e-06	6.72e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ERCC2—melanoma	6.42e-06	6.7e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—FGF2—melanoma	6.37e-06	6.65e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGF—melanoma	6.36e-06	6.64e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PPARG—melanoma	6.34e-06	6.62e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PRKCA—melanoma	6.31e-06	6.59e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—MAPK3—melanoma	6.28e-06	6.56e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ERCC2—melanoma	6.26e-06	6.54e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—MAPK3—melanoma	6.26e-06	6.54e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—BRAF—melanoma	6.17e-06	6.43e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—MAPK3—melanoma	6.16e-06	6.43e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—BRAF—melanoma	6.15e-06	6.41e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP17A1—melanoma	6.1e-06	6.36e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—BRAF—melanoma	6.05e-06	6.31e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IGF1—melanoma	6.01e-06	6.27e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IGF1—melanoma	5.99e-06	6.25e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—melanoma	5.99e-06	6.25e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—MAPK1—melanoma	5.98e-06	6.24e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—EGFR—melanoma	5.98e-06	6.24e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MDM2—melanoma	5.96e-06	6.22e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—MAPK1—melanoma	5.96e-06	6.22e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—EGFR—melanoma	5.96e-06	6.22e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PRKCA—melanoma	5.95e-06	6.21e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ERCC2—melanoma	5.9e-06	6.16e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CD—melanoma	5.89e-06	6.15e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IGF1—melanoma	5.89e-06	6.15e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ERBB2—melanoma	5.88e-06	6.13e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.87e-06	6.13e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—MAPK1—melanoma	5.87e-06	6.12e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—EGFR—melanoma	5.86e-06	6.12e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ALB—melanoma	5.82e-06	6.07e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAP2K1—melanoma	5.8e-06	6.06e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CB—melanoma	5.8e-06	6.05e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAP2K1—melanoma	5.79e-06	6.04e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CD—melanoma	5.77e-06	6.03e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CD—melanoma	5.77e-06	6.02e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GNA11—melanoma	5.76e-06	6.01e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CD—melanoma	5.75e-06	6e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—melanoma	5.71e-06	5.96e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ALB—melanoma	5.7e-06	5.95e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAP2K1—melanoma	5.7e-06	5.94e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—melanoma	5.69e-06	5.94e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CD—melanoma	5.66e-06	5.91e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—melanoma	5.65e-06	5.89e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—FASN—melanoma	5.64e-06	5.88e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—melanoma	5.63e-06	5.87e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	5.6e-06	5.85e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—melanoma	5.57e-06	5.82e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC5A5—melanoma	5.54e-06	5.79e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—melanoma	5.54e-06	5.78e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRAS—melanoma	5.54e-06	5.78e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FGF2—melanoma	5.52e-06	5.76e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FGF2—melanoma	5.5e-06	5.74e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ABCB1—melanoma	5.48e-06	5.72e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1B—melanoma	5.44e-06	5.68e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FGF2—melanoma	5.42e-06	5.65e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—melanoma	5.38e-06	5.62e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GNAQ—melanoma	5.35e-06	5.59e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CD44—melanoma	5.35e-06	5.59e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP3—melanoma	5.33e-06	5.57e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—melanoma	5.33e-06	5.56e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.31e-06	5.55e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL6—melanoma	5.3e-06	5.53e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—melanoma	5.19e-06	5.42e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—melanoma	5.19e-06	5.41e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—melanoma	5.17e-06	5.4e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MDM2—melanoma	5.17e-06	5.39e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MDM2—melanoma	5.15e-06	5.37e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CTNNB1—melanoma	5.14e-06	5.37e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CB—melanoma	5.14e-06	5.36e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1B1—melanoma	5.13e-06	5.36e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB2—melanoma	5.09e-06	5.32e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—melanoma	5.09e-06	5.31e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	5.09e-06	5.31e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB2—melanoma	5.08e-06	5.3e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MDM2—melanoma	5.07e-06	5.29e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CG—melanoma	5.07e-06	5.29e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—melanoma	5.04e-06	5.26e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PRKCA—melanoma	5.04e-06	5.26e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CB—melanoma	5.03e-06	5.25e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CB—melanoma	5.03e-06	5.25e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1A—melanoma	5.02e-06	5.24e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—melanoma	5.01e-06	5.23e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CB—melanoma	5.01e-06	5.23e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ERCC2—melanoma	5e-06	5.22e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB2—melanoma	5e-06	5.22e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NFKB1—melanoma	4.99e-06	5.21e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—melanoma	4.99e-06	5.2e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CG—melanoma	4.95e-06	5.16e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CB—melanoma	4.93e-06	5.15e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PPARG—melanoma	4.89e-06	5.1e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—melanoma	4.89e-06	5.1e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—melanoma	4.83e-06	5.04e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—melanoma	4.81e-06	5.02e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRAS—melanoma	4.8e-06	5.01e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRAS—melanoma	4.78e-06	4.99e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPARG—melanoma	4.77e-06	4.98e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—melanoma	4.74e-06	4.95e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1B—melanoma	4.72e-06	4.92e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRAS—melanoma	4.71e-06	4.91e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1B—melanoma	4.7e-06	4.91e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—melanoma	4.67e-06	4.87e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CG—melanoma	4.66e-06	4.86e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—melanoma	4.65e-06	4.85e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1B—melanoma	4.63e-06	4.83e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP3—melanoma	4.62e-06	4.82e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—melanoma	4.62e-06	4.82e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP3—melanoma	4.61e-06	4.81e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—melanoma	4.6e-06	4.8e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL6—melanoma	4.59e-06	4.79e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—melanoma	4.58e-06	4.78e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL6—melanoma	4.58e-06	4.78e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP3—melanoma	4.54e-06	4.73e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—melanoma	4.53e-06	4.73e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—melanoma	4.53e-06	4.72e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL6—melanoma	4.51e-06	4.7e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—melanoma	4.5e-06	4.7e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPARG—melanoma	4.5e-06	4.69e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—melanoma	4.49e-06	4.68e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—melanoma	4.48e-06	4.68e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NRAS—melanoma	4.47e-06	4.67e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CTNNB1—melanoma	4.46e-06	4.65e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CD—melanoma	4.45e-06	4.65e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CTNNB1—melanoma	4.44e-06	4.64e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—melanoma	4.44e-06	4.63e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—melanoma	4.42e-06	4.61e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ALB—melanoma	4.4e-06	4.59e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CTNNB1—melanoma	4.37e-06	4.56e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—melanoma	4.37e-06	4.56e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—melanoma	4.35e-06	4.54e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1A—melanoma	4.35e-06	4.54e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—melanoma	4.35e-06	4.54e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CD—melanoma	4.35e-06	4.54e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—melanoma	4.34e-06	4.53e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1A—melanoma	4.34e-06	4.53e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—melanoma	4.33e-06	4.52e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NFKB1—melanoma	4.32e-06	4.51e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NFKB1—melanoma	4.31e-06	4.5e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ALB—melanoma	4.29e-06	4.48e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—melanoma	4.29e-06	4.47e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK3—melanoma	4.28e-06	4.47e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1A—melanoma	4.27e-06	4.46e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—melanoma	4.26e-06	4.45e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NFKB1—melanoma	4.24e-06	4.43e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—melanoma	4.24e-06	4.42e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ABCB1—melanoma	4.23e-06	4.41e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—melanoma	4.22e-06	4.41e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—melanoma	4.17e-06	4.35e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—melanoma	4.16e-06	4.34e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.14e-06	4.32e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CD—melanoma	4.1e-06	4.28e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK1—melanoma	4.07e-06	4.25e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—melanoma	4.07e-06	4.25e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ALB—melanoma	4.04e-06	4.22e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CG—melanoma	3.95e-06	4.12e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—melanoma	3.92e-06	4.09e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—melanoma	3.91e-06	4.08e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PRKCA—melanoma	3.89e-06	4.06e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—melanoma	3.88e-06	4.05e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CB—melanoma	3.88e-06	4.05e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NRAS—melanoma	3.87e-06	4.04e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—melanoma	3.87e-06	4.04e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NRAS—melanoma	3.86e-06	4.03e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ERCC2—melanoma	3.86e-06	4.03e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—melanoma	3.85e-06	4.02e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—melanoma	3.85e-06	4.02e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—melanoma	3.85e-06	4.02e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—melanoma	3.81e-06	3.98e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPARG—melanoma	3.81e-06	3.98e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NRAS—melanoma	3.8e-06	3.97e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CB—melanoma	3.79e-06	3.96e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—melanoma	3.75e-06	3.92e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK3—melanoma	3.71e-06	3.87e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK3—melanoma	3.7e-06	3.86e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK3—melanoma	3.64e-06	3.8e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—melanoma	3.61e-06	3.77e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—melanoma	3.6e-06	3.75e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CB—melanoma	3.57e-06	3.73e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—melanoma	3.54e-06	3.7e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—melanoma	3.54e-06	3.69e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—melanoma	3.54e-06	3.69e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK1—melanoma	3.53e-06	3.69e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—melanoma	3.53e-06	3.68e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK1—melanoma	3.52e-06	3.67e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—melanoma	3.52e-06	3.67e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CD—melanoma	3.47e-06	3.62e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK1—melanoma	3.46e-06	3.62e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—melanoma	3.46e-06	3.62e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ALB—melanoma	3.43e-06	3.58e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—melanoma	3.42e-06	3.57e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—melanoma	3.35e-06	3.5e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—melanoma	3.33e-06	3.48e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—melanoma	3.32e-06	3.47e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—melanoma	3.27e-06	3.42e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—melanoma	3.27e-06	3.42e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRAS—melanoma	3.27e-06	3.41e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—melanoma	3.13e-06	3.27e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL6—melanoma	3.13e-06	3.27e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—melanoma	3.09e-06	3.22e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—melanoma	3.07e-06	3.2e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—melanoma	3.06e-06	3.2e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—melanoma	3.05e-06	3.19e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CG—melanoma	3.05e-06	3.18e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CB—melanoma	3.03e-06	3.16e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—melanoma	3.01e-06	3.14e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—melanoma	3e-06	3.13e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—melanoma	2.96e-06	3.09e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—melanoma	2.95e-06	3.08e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPARG—melanoma	2.94e-06	3.07e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—melanoma	2.91e-06	3.04e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—melanoma	2.89e-06	3.01e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRAS—melanoma	2.83e-06	2.96e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRAS—melanoma	2.83e-06	2.95e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRAS—melanoma	2.78e-06	2.9e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6—melanoma	2.71e-06	2.83e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6—melanoma	2.7e-06	2.82e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CD—melanoma	2.68e-06	2.8e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6—melanoma	2.66e-06	2.78e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ALB—melanoma	2.64e-06	2.76e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—melanoma	2.61e-06	2.73e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—melanoma	2.56e-06	2.67e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—melanoma	2.51e-06	2.62e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—melanoma	2.5e-06	2.61e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—melanoma	2.49e-06	2.6e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—melanoma	2.46e-06	2.56e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—melanoma	2.37e-06	2.47e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CB—melanoma	2.33e-06	2.44e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—melanoma	2.31e-06	2.41e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—melanoma	2.31e-06	2.41e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—melanoma	2.18e-06	2.27e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—melanoma	2.02e-06	2.11e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—melanoma	1.93e-06	2.02e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—melanoma	1.89e-06	1.97e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—melanoma	1.84e-06	1.92e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—melanoma	1.78e-06	1.86e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—melanoma	1.51e-06	1.57e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—melanoma	1.42e-06	1.49e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—melanoma	1.16e-06	1.21e-05	CbGpPWpGaD
